Winkler David T, Biedermann Luc, Tolnay Markus, Allegrini Peter R, Staufenbiel Matthias, Wiessner Christoph, Jucker Mathias
Department of Neuropathology, Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland.
Ann Neurol. 2002 Jun;51(6):790-3. doi: 10.1002/ana.10210.
We studied the impact of cerebral amyloid angiopathy on tissue plasminogen activator-induced cerebral hemorrhages in APP23 transgenic mice. Results show that the intravenous administration of tissue plasminogen activator in APP23 mice leads to an increase in cerebral amyloid angiopathy-associated microhemorrhages and can provoke parenchymal and subarachnoidal hematomas. We conclude that cerebral amyloid angiopathy is a risk factor for cerebral hemorrhage caused by tissue plasminogen activator administration in mice and stress the need for more comprehensive studies of the relation between cerebral amyloid angiopathy and tissue plasminogen activator-induced cerebral hemorrhages in elderly and Alzheimer's disease patients.
我们研究了脑淀粉样血管病对组织型纤溶酶原激活剂诱导的APP23转基因小鼠脑出血的影响。结果显示,在APP23小鼠中静脉注射组织型纤溶酶原激活剂会导致脑淀粉样血管病相关的微出血增加,并可引发实质内和蛛网膜下腔血肿。我们得出结论,脑淀粉样血管病是小鼠中因使用组织型纤溶酶原激活剂而导致脑出血的一个危险因素,并强调需要对老年和阿尔茨海默病患者脑淀粉样血管病与组织型纤溶酶原激活剂诱导的脑出血之间的关系进行更全面的研究。